Answers are grounded in this paper and cite their sources.
In this comparative effectiveness study, ICIs were more effective than taxanes in patients with mCRPC when TMB was 10 mt/Mb or greater but not when TMB was fewer than 10 mt/Mb. The results add validity to the existing TMB cutoff of 10 mt/Mb for ICI use in later lines of therapy, and suggest that ICIs may be a viable alternative to taxane chemotherapy for patients with mCRPC with high TMB.
No takes yet. Share an insight, caveat, or question.
Graf et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: